Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic
factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver …

Background & Aims Statins have been variably shown to decrease risk and complications of
chronic liver diseases (CLDs). We performed a systematic review and meta-analysis to …

Material de distribuição exclusiva à classe médica. Os Arquivos Brasileiros de Cardiologia
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …

Background & Aims The combination of β-blockers and band ligation is the standard
approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid …

Background & Aims Recent evidence suggests potential clinical benefits of statin in cancer
chemoprevention and treatment. Nonalcoholic fatty liver disease (NAFLD) is expected to …

Abstract β‐Catenin, the downstream effector of the Wnt signaling, plays important roles in
hepatic development, regeneration, and tumorigenesis. However, its role at hepatocyte …

Background & Aims Statins decrease portal pressure in patients with cirrhosis and increase
survival times of patients who have bled from varices. However, statins can be hepatotoxic. It …

Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular
carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most …

Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and
the predictors of these effects remain unclear. This meta-analysis provides a pooled …

Purpose of review The purpose of this study is to analyze the current evidence regarding the
use of statins in patients with chronic liver disease and cirrhosis. Recent findings Chronic …